Anti-sclerostin antibody treatment in a rat model of progressive renal osteodystrophy

Sharon Moe, Xuening (Neal) Chen, Christopher L. Newman, Jason Organ, Michaela Kneissel, Ina Kramer, Vincent H. Gattone, Matthew Allen

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Chronic kidney disease (CKD) is associated with abnormalities in bone quantity and quality, leading to increased fractures. Recent studies suggest abnormalities of Wnt signaling in animal models of CKD and elevated sclerostin levels in patients with CKD. The goal of this study was to evaluate the effectiveness of anti-sclerostin antibody treatment in an animal model of progressive CKD with low and high parathyroid hormone (PTH) levels. Cy/+ male rats (CKD) were treated without or with calcium in the drinking water at 25 weeks of age to stratify the animals into high PTH and low PTH groups, respectively, by 30 weeks. Animals were then treated with anti-sclerostin antibody at 100 mg/kg i.v. weekly for 5 doses, a single 20-µg/kg subcutaneous dose of zoledronic acid, or no treatment, and were then euthanized at 35 weeks. As a positive control, the efficacy of anti-sclerostin antibody treatment was also evaluated in normal littermates. The results demonstrated that the CKD animals with high PTH had lower calcium, higher phosphorus, and lower FGF23 compared to the CKD animals with low PTH. Treatment with anti-sclerostin antibody had no effect on any of the biochemistries, whereas zoledronic acid lowered dkk-1 levels. The anti-sclerostin antibody increased trabecular bone volume/total volume (BV/TV) and trabecular mineralization surface in animals with low PTH, but not in animals with high PTH. Neither anti-sclerostin antibody nor zoledronic acid improved biomechanical properties in the animals. Cortical porosity was severe in high-PTH animals and was unaffected by either treatment. In contrast, in normal animals treated with anti-sclerostin antibody, there was an improvement in bone volume, cortical geometry, and biomechanical properties. In summary, this is the first study to test the efficacy of anti-sclerostin antibody treatment on animals with advanced CKD. We found efficacy in improving bone properties only when the PTH levels were low.

Original languageEnglish (US)
Pages (from-to)499-509
Number of pages11
JournalJournal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
Volume30
Issue number3
DOIs
StatePublished - Mar 1 2015

Fingerprint

Chronic Kidney Disease-Mineral and Bone Disorder
Parathyroid Hormone
Anti-Idiotypic Antibodies
Chronic Renal Insufficiency
zoledronic acid
Therapeutics
Animal Models
Calcium
Bone and Bones
Porosity
Drinking Water
Biochemistry
Phosphorus

Keywords

  • CKD-MBD
  • FGF23
  • PARATHYROID HORMONE
  • RENAL OSTEODYSTROPHY
  • SCLEROSTIN
  • WNT

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Anti-sclerostin antibody treatment in a rat model of progressive renal osteodystrophy. / Moe, Sharon; Chen, Xuening (Neal); Newman, Christopher L.; Organ, Jason; Kneissel, Michaela; Kramer, Ina; Gattone, Vincent H.; Allen, Matthew.

In: Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, Vol. 30, No. 3, 01.03.2015, p. 499-509.

Research output: Contribution to journalArticle

@article{70b0f0749cd3425d9ee96891e7566d38,
title = "Anti-sclerostin antibody treatment in a rat model of progressive renal osteodystrophy",
abstract = "Chronic kidney disease (CKD) is associated with abnormalities in bone quantity and quality, leading to increased fractures. Recent studies suggest abnormalities of Wnt signaling in animal models of CKD and elevated sclerostin levels in patients with CKD. The goal of this study was to evaluate the effectiveness of anti-sclerostin antibody treatment in an animal model of progressive CKD with low and high parathyroid hormone (PTH) levels. Cy/+ male rats (CKD) were treated without or with calcium in the drinking water at 25 weeks of age to stratify the animals into high PTH and low PTH groups, respectively, by 30 weeks. Animals were then treated with anti-sclerostin antibody at 100 mg/kg i.v. weekly for 5 doses, a single 20-µg/kg subcutaneous dose of zoledronic acid, or no treatment, and were then euthanized at 35 weeks. As a positive control, the efficacy of anti-sclerostin antibody treatment was also evaluated in normal littermates. The results demonstrated that the CKD animals with high PTH had lower calcium, higher phosphorus, and lower FGF23 compared to the CKD animals with low PTH. Treatment with anti-sclerostin antibody had no effect on any of the biochemistries, whereas zoledronic acid lowered dkk-1 levels. The anti-sclerostin antibody increased trabecular bone volume/total volume (BV/TV) and trabecular mineralization surface in animals with low PTH, but not in animals with high PTH. Neither anti-sclerostin antibody nor zoledronic acid improved biomechanical properties in the animals. Cortical porosity was severe in high-PTH animals and was unaffected by either treatment. In contrast, in normal animals treated with anti-sclerostin antibody, there was an improvement in bone volume, cortical geometry, and biomechanical properties. In summary, this is the first study to test the efficacy of anti-sclerostin antibody treatment on animals with advanced CKD. We found efficacy in improving bone properties only when the PTH levels were low.",
keywords = "CKD-MBD, FGF23, PARATHYROID HORMONE, RENAL OSTEODYSTROPHY, SCLEROSTIN, WNT",
author = "Sharon Moe and Chen, {Xuening (Neal)} and Newman, {Christopher L.} and Jason Organ and Michaela Kneissel and Ina Kramer and Gattone, {Vincent H.} and Matthew Allen",
year = "2015",
month = "3",
day = "1",
doi = "10.1002/jbmr.2372",
language = "English (US)",
volume = "30",
pages = "499--509",
journal = "Journal of Bone and Mineral Research",
issn = "0884-0431",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Anti-sclerostin antibody treatment in a rat model of progressive renal osteodystrophy

AU - Moe, Sharon

AU - Chen, Xuening (Neal)

AU - Newman, Christopher L.

AU - Organ, Jason

AU - Kneissel, Michaela

AU - Kramer, Ina

AU - Gattone, Vincent H.

AU - Allen, Matthew

PY - 2015/3/1

Y1 - 2015/3/1

N2 - Chronic kidney disease (CKD) is associated with abnormalities in bone quantity and quality, leading to increased fractures. Recent studies suggest abnormalities of Wnt signaling in animal models of CKD and elevated sclerostin levels in patients with CKD. The goal of this study was to evaluate the effectiveness of anti-sclerostin antibody treatment in an animal model of progressive CKD with low and high parathyroid hormone (PTH) levels. Cy/+ male rats (CKD) were treated without or with calcium in the drinking water at 25 weeks of age to stratify the animals into high PTH and low PTH groups, respectively, by 30 weeks. Animals were then treated with anti-sclerostin antibody at 100 mg/kg i.v. weekly for 5 doses, a single 20-µg/kg subcutaneous dose of zoledronic acid, or no treatment, and were then euthanized at 35 weeks. As a positive control, the efficacy of anti-sclerostin antibody treatment was also evaluated in normal littermates. The results demonstrated that the CKD animals with high PTH had lower calcium, higher phosphorus, and lower FGF23 compared to the CKD animals with low PTH. Treatment with anti-sclerostin antibody had no effect on any of the biochemistries, whereas zoledronic acid lowered dkk-1 levels. The anti-sclerostin antibody increased trabecular bone volume/total volume (BV/TV) and trabecular mineralization surface in animals with low PTH, but not in animals with high PTH. Neither anti-sclerostin antibody nor zoledronic acid improved biomechanical properties in the animals. Cortical porosity was severe in high-PTH animals and was unaffected by either treatment. In contrast, in normal animals treated with anti-sclerostin antibody, there was an improvement in bone volume, cortical geometry, and biomechanical properties. In summary, this is the first study to test the efficacy of anti-sclerostin antibody treatment on animals with advanced CKD. We found efficacy in improving bone properties only when the PTH levels were low.

AB - Chronic kidney disease (CKD) is associated with abnormalities in bone quantity and quality, leading to increased fractures. Recent studies suggest abnormalities of Wnt signaling in animal models of CKD and elevated sclerostin levels in patients with CKD. The goal of this study was to evaluate the effectiveness of anti-sclerostin antibody treatment in an animal model of progressive CKD with low and high parathyroid hormone (PTH) levels. Cy/+ male rats (CKD) were treated without or with calcium in the drinking water at 25 weeks of age to stratify the animals into high PTH and low PTH groups, respectively, by 30 weeks. Animals were then treated with anti-sclerostin antibody at 100 mg/kg i.v. weekly for 5 doses, a single 20-µg/kg subcutaneous dose of zoledronic acid, or no treatment, and were then euthanized at 35 weeks. As a positive control, the efficacy of anti-sclerostin antibody treatment was also evaluated in normal littermates. The results demonstrated that the CKD animals with high PTH had lower calcium, higher phosphorus, and lower FGF23 compared to the CKD animals with low PTH. Treatment with anti-sclerostin antibody had no effect on any of the biochemistries, whereas zoledronic acid lowered dkk-1 levels. The anti-sclerostin antibody increased trabecular bone volume/total volume (BV/TV) and trabecular mineralization surface in animals with low PTH, but not in animals with high PTH. Neither anti-sclerostin antibody nor zoledronic acid improved biomechanical properties in the animals. Cortical porosity was severe in high-PTH animals and was unaffected by either treatment. In contrast, in normal animals treated with anti-sclerostin antibody, there was an improvement in bone volume, cortical geometry, and biomechanical properties. In summary, this is the first study to test the efficacy of anti-sclerostin antibody treatment on animals with advanced CKD. We found efficacy in improving bone properties only when the PTH levels were low.

KW - CKD-MBD

KW - FGF23

KW - PARATHYROID HORMONE

KW - RENAL OSTEODYSTROPHY

KW - SCLEROSTIN

KW - WNT

UR - http://www.scopus.com/inward/record.url?scp=84964694420&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964694420&partnerID=8YFLogxK

U2 - 10.1002/jbmr.2372

DO - 10.1002/jbmr.2372

M3 - Article

C2 - 25407607

AN - SCOPUS:84922932317

VL - 30

SP - 499

EP - 509

JO - Journal of Bone and Mineral Research

JF - Journal of Bone and Mineral Research

SN - 0884-0431

IS - 3

ER -